Myasterix is a clinical-stage biotech company that focuses on developing Therapeutic Vaccines for the treatment of autoimmune diseases. Founded by Dr. Stéphane Huberty, a Belgian medical doctor who himself suffered from Myasthenia Gravis (MG), Myasterix aims to revolutionize medical and commercial potential through its innovative production technique.

One of their breakthrough products is the MG Therapeutic Vaccine, CV-MG02, which has shown promising results in a phase 1B clinical trial. The vaccine has demonstrated an excellent safety profile and is now being prepared for a phase 2 efficacy clinical trial. Myasterix's expertise extends beyond MG, as they plan to develop Therapeutic Vaccines for other autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and systemic lupus erythematosus.

With autoimmune diseases affecting more than five percent of the western population, the importance of Myasterix's work cannot be understated. Join them in their mission to provide effective treatments and enhance the lives of those suffering from these conditions